Market Overview

Merck Returns Rights for Vernakalant to Cardiome

Share:
Related MRK
Pharma Names Under Pressure Amid Perrigo Warning
After-Hours Recap: Big Banks, Liquidity Services's DoD Deal, Haemonetics' CFO & More
Ligand Pharma Adds Tech, Grows On Partners' Success (Investor's Business Daily)
Related CRME
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency
Cardiome Reports ~$15M Bought-Deal Financing

Cardiome Pharma Corp. (Nasdaq: CRME) (TSX:COM) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Merck will return the global marketing and development rights for both the intravenous (IV) and oral formulations for vernakalant to Cardiome.

Vernakalant IV is marketed, in certain countries, under the brand name BRINAVESS.^TM BRINAVESS was approved in the European Union on September 1, 2010 for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults: for non-surgery patients with AF of seven days or less and for post-cardiac surgery patients with AF of three days or less.  Vernakalant IV is not approved for use in the United States or Canada.

Posted-In: News FDA

 

Related Articles (CRME + MRK)

View Comments and Join the Discussion!